ClinicalTrials.gg
Not yet recruitingNCT07331493Updated Feb 11, 2026

Establishing a Minimum Predictive Threshold Follicular Size and Oocyte Retrieval in ICSI Cycle

An observational study in Female Infertility, sponsored by Assiut University. Not yet recruiting at 1 site in Egypt. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Assiut University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Infertility, Female with a site in Egypt — 6 open to participants now, 6 under way, none of them phase 3. Infertility, Female · Egypt.

Planned enrollment
12th of 14
60 · median 163
Started
2026
with 2 others
Observational
14 of 60
2 open now
Registered
56th of 60
by date
Lead sponsor
5 of 60
Assiut University

Among the 60 studies in Infertility, Female with a site in Egypt, this one is the 12th largest by planned enrollment of the 14 observational ones that give a count, is one of 3 that started in 2026, is one of 14 observational ones, and was the 56th registered.

Infertility, Female

553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.

Browse Infertility, Female studies →

Open to participants now

6 of the 60 studies in Infertility, Female with a site in Egypt are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 88 Infertility, Female studies recruiting now, 11 (13%) set no upper age limit and 77 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 35 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Infertility, Female with a site in Egypt, or all of them as a file.
02

Study summary

This study uses number and size of ovarian follicles on the day of ovulation trigger as key determinants for oocytes yield to optimize outcomes in IVF and ICSI Protocols

Read the detailed description

Accurate prediction of oocyte yield is a key factor in optimizing outcomes of in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) cycles. Follicle number and follicle diameter measured on the day of ovulation trigger are known to be strongly associated with oocyte retrieval and oocyte maturity. Larger follicles are more likely to yield mature (metaphase-II) oocytes, while smaller follicles contribute less consistently to oocyte yield.

Despite the established association between follicular size and oocyte maturity, there is currently no standardized clinical model that estimates the minimum expected number of retrieved oocytes based on the distribution of follicle diameters on the trigger day. Most existing studies focus on average outcomes rather than providing a practical tool to estimate the lowest anticipated oocyte yield for individual patients.

This study aims to estimate the minimum number of oocytes retrieved based on the number and diameter of ovarian follicles measured on the day of ovulation trigger. By developing a predictive approach based on follicular size distribution, this study seeks to support clinical decision-making, optimize trigger timing, and improve patient counseling regarding realistic expectations of oocyte yield.

03

Conditions studied

  • Female Infertility

Browse trials for

Keywords

  • ICSI
  • Follicular size
  • Oocyte Retrieval
  • Oocyte yield
  • assisted reproduction
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Female participants aged 18 to 35 years undergoing ICSI

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women aged 18 to 35 years undergoing ICSI.
  • at least four follicles above 15 mm in diameter on the day of trigger
  • Downregulation using either GNRH antagonist or agonist protocol
  • Provision of written ,
  • 18 to 35 kg per meter square

Exclusion criteria

Exclusion Criteria:

  • anticipated poor responder, according to Bologna criteria
  • cycle canceled prior to retrieval or without trigger administration
  • Oocyte cryoperservation cycles or natural IVF cycles
  • presence of ovarian pathology affecting the follicular assessment (endometriosis,cysts )
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Target follow-up
7 Weeks
Patient registry
Yes

Groups and cohorts

  • ICSI observational Cohort

    Participants will undergo standard ICSI procedures. Follicle size and number will be measured during ovarian stimulation; and oocyte yield will be see corded at retrieval. No additional interventions will be performed. The study aims to evaluate the predictive relationship between follicle characteristics and Oocyte yield

06

What researchers measure

Primary outcomes

  1. Total number of oocytes retrieved per participant during an ICSI cycle

    The total number of oocytes retrieved will be recorded for each participant. Follicular number and mean follicular diameter will be measured by transvaginal ultrasound during ovarian stimulation, and their association with oocyte yield will be analyzed to determine minimum predictive thresholds for successful oocyte retrieval.

    Time frame: From the start of controlled ovarian stimulation until the day of oocyte retrieval, assessed at oocyte retrieval (approximately 10-14 days after stimulation initiation and 34-36 hours after ovulation trigger).

Secondary outcomes

  1. Oocyte yield stratified by follicle size category and age group

    The total number of oocytes retrieved per participant will be recorded and analyzed according to follicle size categories on the day of ovulation trigger. Participants will be stratified into predefined age groups (18-29 years and 30-35 years), and oocyte yield per follicle size category will be compared between age groups.

    Time frame: From the start of controlled ovarian stimulation until the day of oocyte retrieval, assessed at oocyte retrieval (approximately 10-14 days after stimulation initiation and 34-36 hours after ovulation trigger).

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — No plan to share individual participant data is currently in place for this study

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Dec 2029, 44 months later.

Of 85 non-industry observational studies under Infertility, Female, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 69. This study's planned 44 months is above that.

Counting every sponsor, half of 88 studies reached it within 36 months; a quarter within 18 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Jan 12, 2026
StartEst.
Apr 30, 2026
Primary completionEst.
Dec 30, 2029
CompletionEst.
Dec 30, 2030
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07331493
Lead sponsor
Assiut University
Responsible party
Ahmad Rashad Mahmoud Mostafa (Dr, Assiut University) — Principal investigator
First posted
Jan 12, 2026
Start date
Apr 30, 2026 (estimated)
Primary completion
Dec 30, 2029 (estimated)
Completion
Dec 30, 2030 (estimated)
Last update
Feb 11, 2026

Study contacts

Ahmad Rashad Mahmoud Mostafa, MBBCh
Contact
dr.arm99256@outlook.com
+201015655880
Karima Sobhy M.Kholeif, Ph.D.
Contact
Karema55@yahoo.com
+01092698985
Alaa Ahmed Makhlouf, MD
study chair · Assiut University
Ahmed Abo-Elfadle, MD
study chair · Assiut University
Ahmed Mohamed Abo Elhasan Morsy, MD
study chair · Assiut University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion